These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14616152)

  • 1. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
    Pehlivanov ND; Olyaee M; Sarosiek I; McCallum RW
    Aliment Pharmacol Ther; 2003 Nov; 18(9):883-90. PubMed ID: 14616152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
    Miner P; Delemos B; Xiang J; Lococo J; Ieni J
    Aliment Pharmacol Ther; 2010 May; 31(9):991-1000. PubMed ID: 20132153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Hendel J; Hendel L; Aggestrup S
    Aliment Pharmacol Ther; 1995 Dec; 9(6):693-7. PubMed ID: 8824658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
    Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
    Warrington S; Baisley K; Lee D; Lomax K; Delemos B; Boyce M; Morocutti A
    Aliment Pharmacol Ther; 2007 Feb; 25(4):511-7. PubMed ID: 17270007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
    Adachi K; Komazawa Y; Fujishiro H; Mihara T; Ono M; Yuki M; Kawamura A; Karim Rumi MA; Amano Y; Kinoshita Y
    J Gastroenterol; 2003; 38(9):830-5. PubMed ID: 14564627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
    Katz PO; Anderson C; Khoury R; Castell DO
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
    Vo L; Simonian HP; Doma S; Fisher RS; Parkman HP
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1321-30. PubMed ID: 15932362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated acidity and rabeprazole pharmacology.
    Gardner JD; Perdomo C; Sloan S; Hahne WF; Barth JA; Rodriguez-Stanley S; Robinson M
    Aliment Pharmacol Ther; 2002 Mar; 16(3):455-64. PubMed ID: 11876698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Jul; 18(1):133-40. PubMed ID: 12848635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.